A previous study also supports the protective effect of pyroptosis on melanoma: BRAFi and MEKi targeted therapy induces GSDME cleavage and mediates pyroptosis, but BRAFi + MEKi-resistant disease lacks pyroptosis markers [14], suggesting possible interaction with pyroptosis and the RAS-RAF-MEK-ERK (MAPK) pathway. The gene discussed is MAP2K7; the disease is melanoma.